Orally active non-steroidal androgen receptor antagonist (IC50
= 190 nM). Displays peripheral selectivity and does not effect serum levels of LH and testosterone. Exhibits potent anticancer activity in vivo
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold for research purposes only under agreement from AstraZeneca
ICI 176,334: a novel non-steroidal, peripherally selective antiandrogen.
Furr et al.
Nonsteroidal antiandrogens. Synthesis and structure-activity relationships of 3-substituted derivatives of 2-hydroxypropionanilides.
Tucker et al.
The preclinical development of bicalutamide: pharmacodynamics and mechanism of action.
Furr and Tucker
The citations listed below are publications that use Tocris products. Selected citations for Bicalutamide include:
Showing Results 1 - 3 of 3